Target intelligence / Profile preview

Fermentation by colonic bacteria

Molecular classification
Other
01

Overview

**Fermentation by colonic bacteria** describes the metabolic activities of the gut microbiota in the large intestine, where complex carbohydrates, proteins, and endogenous substrates that escape digestion in the upper gastrointestinal tract are broken down. The primary products are **short-chain fatty acids (SCFA)**, particularly acetate, propionate, and butyrate, which support colonic epithelial health, influence systemic metabolism, regulate inflammation, and may have protective roles against colorectal cancer. The process involves a wide diversity of bacterial species (e.g., Firmicutes like Lachnospiraceae, *Faecalibacterium prausnitzii*, and *Bacteroides* species) and is highly substrate-dependent, modulating both the microbiome composition and functional output. Fermentation is not a single molecule or defined structure, but a complex, community-driven set of biochemical reactions essential for gastrointestinal and systemic health[1][2][3][4][5]. **Note:** This entry is not a receptor, protein, or individual molecular target, and thus is not suited for structured molecular target annotation for therapeutic development. If a molecular target related to this process is desired, a specific enzyme, bacterial species, or metabolite pathway should be indicated.

Other names
Colonic bacterial fermentationGut microbial fermentationColonic fermentation
02

Biological functions

Digestion of dietary fiber and undigested carbohydratesDigestion of proteinsProduction of short-chain fatty acids (SCFA) such as acetate, propionate, and butyrateMetabolism of polyphenols, amino acids, and bile acidsModulation of colonic epithelial healthRegulation of luminal pH
03

Disease associations

Inflammation (e.g., colitis: altered fermentation products may contribute to gut inflammation)Cancer (e.g., butyrate has anti-carcinogenic properties)Cardiometabolic diseases (e.g., SCFA ratios influence systemic metabolism)Obesity/metabolic syndrome (via SCFA)Other (general gastrointestinal conditions and microbe-dependent metabolic disorders)
04

Safety considerations

Excessive production of potentially toxic fermentation metabolites (ammonia, phenols, amines)Dysbiosis (imbalance in bacterial populations may lead to unhealthy fermentation profiles)
05

Biomarkers

SCFA concentrations (acetate, propionate, butyrate)Specific bacterial taxa abundance (e.g., *Faecalibacterium prausnitzii*, *Roseburia*, *Ruminococcaceae*, *Bacteroides* spp.)Branched-chain fatty acids (BCFA) levels

Beyond the preview

Go deeper on Fermentation by colonic bacteria.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fermentation by colonic bacteria.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call